A number of studies have shown that in insomnia, poor quality rather than quantity of sleep is associated with impaired daytime functioning, poor physical and mental health and Quality of Life1.
In general, sleep drugs have been approved on the basis of improvements of falling asleep and/or sleep maintenance but not in sleep quality and next day performance2 3. Circadin® is the only drug that also shows improvements in both sleep quality and morning alertness.
A six months trial4 showed that Circadin®:
- Decreased Sleep latency
- Increased Total sleep time
- Improved Quality of Sleep
- Improved Morning alertness
- Improved Quality of Life
- Improved Global impression
- Advanced Time to go to bed
- Maintained good Safety profile
Circadin® improves Quality of Sleep
Circadin® improves sleep quality in primary insomnia patients aged 55 years and over6.
Circadin® improves sleep latency
Circadin® improves sleep latency in patients 55 and older. It was shown that Circadin® effect on sleep latency improved with time, up to 13 weeks and maintained up to 6 months7.
Circadin® is as effective as Zopiclone in shortening the time it takes to fall asleep without Zopiclone’s mild and severe side effects. In the same study there was no significant difference between Circadin® and Zopiclone in total sleep time, sleep latency, number of awakenings or time spent awake after sleep onset8.
Circadin® improves morning alertness
Sleep better, wake fresher, get more out of life.
Circadin® helps the body restore its optimal sleep-wake cycle, so that patients awake refreshed and alert.6
Circadin® improves Quality of Life
A good sleep affects everybody and has an impact on health, morning alertness, daytime functioning, satisfaction and lifestyle. Circadin® is fulfilling the unmet needs of insomniacs in quality, refreshing sleep and improves Quality of Life6.
Long term efficacy
In a long term study5 conducted on adults (18-80) with primary insomnia, Circadin® significantly reduced patient reported sleep latency and improved sleep quality, daytime alertness and Quality of Life, compared to placebo in patients aged 55-80.
Moreover, this controlled study’s results confirmed that efficacy is building up and enhanced with continuous use over 13 weeks and maintained thereafter for at least 6 months. Percentage of responders increased from 3 weeks to 3 months by 10%.
